View printer-friendly version

Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies

Company Receives Its First Ebola-Related BARDA Task Order for Its HHS-Designated Center for Innovation in Advanced Development and Manufacturing
GAITHERSBURG, Md., July 20, 2015 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2000 Liter scale. This contract is the first BARDA Task Order for an Ebola countermeasure awarded to Emergent under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. Under the scope of this two-year contract, the company will conduct process development, analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance.

“Emergent is pleased to work with BARDA on this contract, which reflects the government’s commitment to enhancing public-private partnerships and, together, taking steps to achieve a state of readiness against emerging public health threats,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions. “We look forward to working collaboratively with the government to further this important program.”

The monoclonal antibodies will be manufactured at Emergent’s Bayview Campus in Baltimore, which is equipped with disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products with a quick turnaround. In 2012, it was designated by the U.S. Department of Health and Human Services as a Center for Innovation in Advanced Development and Manufacturing, which allows the company to contract with the U.S. government through task order requests for requirements such as operational readiness, development and manufacturing of CBRN products, warm base maintenance, surge manufacturing, and workforce development. In this facility, Emergent has successfully manufactured product candidates for the company’s pipeline and for ongoing collaborations, including most recently the MVA-EBOZ Ebola vaccine candidate, which is now being evaluated in a Phase 1 clinical study.

This task order under contract HHS0100201200004I is funded by the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

About Emergent BioSolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

CONTACT: Investor Contact:
         Robert G. Burrows
         Vice President, Investor Relations
         240-631-3280
         BurrowsR@ebsi.com

         Media Contact:
         Tracey Schmitt
         Vice President, Global Public Affairs
         and Corporate Responsibility
         240-631-3394
         SchmittT@ebsi.com
Emergent BioSolutions Inc.
Emergent BioSolutions

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.